Patrice Lee

657 total citations
20 papers, 418 citations indexed

About

Patrice Lee is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Patrice Lee has authored 20 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in Patrice Lee's work include Cancer Mechanisms and Therapy (5 papers), Melanoma and MAPK Pathways (3 papers) and HER2/EGFR in Cancer Research (3 papers). Patrice Lee is often cited by papers focused on Cancer Mechanisms and Therapy (5 papers), Melanoma and MAPK Pathways (3 papers) and HER2/EGFR in Cancer Research (3 papers). Patrice Lee collaborates with scholars based in United States and Italy. Patrice Lee's co-authors include Andres Forero‐Torres, Anita Kulukian, Robert Rosler, Daniel Watson, Scott Peterson, Peter de Vries, James D. Winkler, Karyn Bouhana, Christine Lemieux and Richard Woessner and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Patrice Lee

17 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrice Lee United States 9 177 168 73 58 54 20 418
Margarite D. Matossian United States 14 258 1.5× 314 1.9× 50 0.7× 42 0.7× 18 0.3× 39 588
Sarah Short United States 6 170 1.0× 271 1.6× 63 0.9× 43 0.7× 12 0.2× 10 481
Amar Desai United States 11 185 1.0× 386 2.3× 52 0.7× 39 0.7× 27 0.5× 23 599
K. Garber Austria 10 156 0.9× 311 1.9× 56 0.8× 24 0.4× 29 0.5× 16 521
Dao Doan United States 7 179 1.0× 250 1.5× 71 1.0× 20 0.3× 21 0.4× 11 437
Brendan Pang Singapore 9 210 1.2× 264 1.6× 163 2.2× 30 0.5× 43 0.8× 16 543
Sidharth Mahapatra United States 14 148 0.8× 277 1.6× 84 1.2× 20 0.3× 20 0.4× 32 513
Max Jacobsen United States 12 68 0.4× 257 1.5× 58 0.8× 46 0.8× 28 0.5× 21 412
Alexis S. Lopez United States 6 170 1.0× 226 1.3× 98 1.3× 29 0.5× 27 0.5× 8 495
Ivana Galetić Switzerland 7 64 0.4× 315 1.9× 107 1.5× 31 0.5× 20 0.4× 10 494

Countries citing papers authored by Patrice Lee

Since Specialization
Citations

This map shows the geographic impact of Patrice Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrice Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrice Lee more than expected).

Fields of papers citing papers by Patrice Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrice Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrice Lee. The network helps show where Patrice Lee may publish in the future.

Co-authorship network of co-authors of Patrice Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Patrice Lee. A scholar is included among the top collaborators of Patrice Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrice Lee. Patrice Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ren, Li, David Moreno‐Mateos, Brian R. Baer, et al.. (2024). Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry. 67(15). 13019–13032. 1 indexed citations
2.
3.
Bouhana, Karyn, Walter E. DeWolf, Li Ren, et al.. (2021). Abstract 1473: Nonclinical development of PF-07284890 (ARRY-461), a potent, brain-penetrant, small molecule inhibitor of BRAF V600-mutation-driven tumors in vitro and in vivo. Cancer Research. 81(13_Supplement). 1473–1473. 4 indexed citations
4.
Mehta, Anita K., Madisson Oliwa, Patrice Lee, et al.. (2021). 614 Investigating immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC). SHILAP Revista de lepidopterología. A644–A644. 1 indexed citations
5.
Kulukian, Anita, Patrice Lee, Robert Rosler, et al.. (2020). Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. Molecular Cancer Therapeutics. 19(4). 976–987. 144 indexed citations
6.
Laurini, Erik, Valentina Martinelli, Suet Nee Chen, et al.. (2018). Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins. Cardiovascular Research. 114(6). 846–857. 32 indexed citations
7.
Edwards, David K., Hibery Ho, Christopher A. Eide, et al.. (2018). Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 9(37). 24576–24589. 37 indexed citations
8.
Edwards, David K., Angela Rofelty, Anupriya Agarwal, et al.. (2015). CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes. Blood. 126(23). 3824–3824. 2 indexed citations
9.
Spurgeon, Stephen E., Jeffrey Tyner, Anupriya Agarwal, et al.. (2015). Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL. Blood. 126(23). 4439–4439. 2 indexed citations
10.
Robinson, John M., et al.. (2012). A Dual PIM 1/3 Kinase Inhibitor Demonstrates Efficacy in Murine Models of Lupus and Multiple Sclerosis (119.9). The Journal of Immunology. 188(1_Supplement). 119.9–119.9. 1 indexed citations
11.
Ghilardi, Joseph R., Katie T. Freeman, Juan Miguel Jiménez‐Andrade, et al.. (2010). Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers. Bone. 48(2). 389–398. 53 indexed citations
12.
Bouhana, Karyn, Deborah Anderson, Jennifer Garrus, et al.. (2009). Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2.. Cancer Research. 69. 1795–1795. 20 indexed citations
13.
Woessner, Richard, Brian Tunquist, Christine Lemieux, et al.. (2009). ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.. PubMed. 29(11). 4373–80. 51 indexed citations
14.
Bouhana, Karyn, Rich Woessner, Ira von Carlowitz, et al.. (2008). Differential activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 compared to lapatanib in in vivo xenograft models. Cancer Research. 68. 4848–4848.
15.
Groß, Stefan, John Robinson, Shelley Allen, et al.. (2008). Characterization of the Effects of Pim Kinase Inhibition on Multiple Oncogene-Driven Cell Lines. Blood. 112(11). 2662–2662. 1 indexed citations
16.
Woessner, Richard, Shelley Allen, Qian Zhao, et al.. (2007). ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. Cancer Research. 67. 1433–1433. 9 indexed citations
17.
Huérou, Yvan Le, Indrani W. Gunawardana, Allen A. Thomas, et al.. (2007). Prodrug thiamine analogs as inhibitors of the enzyme transketolase. Bioorganic & Medicinal Chemistry Letters. 18(2). 505–508. 20 indexed citations
18.
19.
Wallace, Eli M., Joseph P. Lyssikatos, James F. Blake, et al.. (2005). Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones. Journal of Medicinal Chemistry. 49(2). 441–444. 34 indexed citations
20.
Matson, James R. & Patrice Lee. (2000). Evolving concepts of therapy for sepsis and septic shock and the use of hyperpermeable membranes. Current Opinion in Critical Care. 6(6). 431–436. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margarite D. Matossian Breakdown of academic impact, for papers by Sarah Short Breakdown of academic impact, for papers by Amar Desai Breakdown of academic impact, for papers by K. Garber Breakdown of academic impact, for papers by Dao Doan Breakdown of academic impact, for papers by Brendan Pang Breakdown of academic impact, for papers by Sidharth Mahapatra Breakdown of academic impact, for papers by Max Jacobsen Breakdown of academic impact, for papers by Alexis S. Lopez Breakdown of academic impact, for papers by Ivana Galetić
Rankless by CCL
2026